<DOC>
	<DOC>NCT01499342</DOC>
	<brief_summary>This is a Belgian prospective multicentre registry to evaluate safety and performance of the Sinus-Superflex-Visual stent (Optimed) in Superficial Femoral Artery (SFA) atherosclerotic lesions. Target number is 500 patients in approximately 11 centres. Patients will be followed for a period of 2 years.</brief_summary>
	<brief_title>Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent in the Superficial Femoral Artery</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Signed informed consent Stenosis (&gt; 75%) or occlusion of the superficial femoral artery (lesion up to 3 cm distal to Hunter's canal and 4 cm proximal to the patella) TASC II (2007)type A, B or C lesions Target vessel diameter between 4.5 and 7 mm Debilitating claudication or critical limb ischemia (Rutherford 2 to 5) At least 1 outflow vessel down to the ankle Patient is at least 18 years old Life expectancy &gt; 2 years Patient is compliant with the requested followup visits No informed consent Rutherford 6 TASC II type D lesions Patient is not 18 years old Patient is pregnant Acute ischemia Patient is not compliant with the requested followup visits Unable to cross target lesion with guidewire Patient is allergic to nickeltitanium Presence of an aneurysm in the SFA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Stent</keyword>
	<keyword>Atherosclerotic occlusive disease</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>Superficial femoral artery</keyword>
	<keyword>SFA</keyword>
</DOC>